Granules India Q1FY26 Revenue at ₹12,101 Mn, Up 3% YoY

Granules India Ltd., a vertically integrated pharmaceutical  company, has announced its financial results for the quarter ended June 30, 2025. 

Financial and Business Summary for Q1FY26 

• Q1FY26 includes Financials of Senn Chemicals AG.
• Revenue from Operations of Q1FY26 stood at INR 12,101 Mn, a growth of 3% YoY, Sales  growth was largely driven by North America.
• Active Pharmaceuticals Ingredients (API), Pharmaceutical Formulation Intermediates (PFI), Finished dosages (FD) and Peptides/ CDMO contribute 14%, 10%, 74% and 2% of  revenue from operations respectively for Q1FY26.
• ROCE is at 16.0% (Post Acquisition of Senn Chemicals AG) as compared to 16.6% YoY. ▪ Net debt stood at INR 9,480 Mn and Net debt to EBITDA at 0.96x.

Commenting on the results, Dr. Krishna Prasad Chigurupati, Chairman & Managing  Director of Granules India Limited said, “We delivered healthy cash flow from operations of  ₹2,806 million this quarter and made good progress on the Gagillapur remediation program.  USFDA audits at our Bonthapally API facility, GPI in Virginia, and Granules Life Sciences at  Genome Valley were successfully completed with one minor observation each. The Danish  Medicines Agency also concluded its EU GMP inspection of Gagillapur with certification granted.  With our near-term formulations growth trajectory set to resume, and the integration of Senn  Chemicals through the Ascelis platform in the fast-growing CDMO sector, we are well-positioned  for sustainable long-term growth”